{"id":9021,"date":"2023-06-14T21:15:34","date_gmt":"2023-06-14T19:15:34","guid":{"rendered":"https:\/\/www.afaf.asso.fr\/?p=9021"},"modified":"2023-06-14T21:19:42","modified_gmt":"2023-06-14T19:19:42","slug":"communique-de-presse-de-lexeo-therapeutics-du-13-03-2023","status":"publish","type":"post","link":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/","title":{"rendered":"Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\/06\/2023"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>R\u00e9sum\u00e9 du communiqu\u00e9 de presse<\/strong><br>LEXEO Therapeutics (LEXEO) est une soci\u00e9t\u00e9 de th\u00e9rapie g\u00e9nique au stade clinique qui d\u00e9veloppe des candidats de th\u00e9rapie g\u00e9nique bas\u00e9s sur un virus ad\u00e9no-associ\u00e9 (AAV).<br>LX2006 est la premi\u00e8re th\u00e9rapie g\u00e9nique exp\u00e9rimentale pour le traitement de la cardiomyopathie due \u00e0 l&#8217;ataxie de Friedreich.<br>SUNRISE-FA est un essai ouvert multicentrique de phase 1\/2 de 52 semaines en escalade de dose qui \u00e9value la s\u00e9curit\u00e9 et la tol\u00e9rabilit\u00e9, ainsi que l&#8217;efficacit\u00e9 pr\u00e9liminaire de LX2006 chez des patients atteints de cardiomyopathie FA. LX2006 est administr\u00e9 en une seule perfusion intraveineuse aux patients dans au moins deux cohortes de doses croissantes. La s\u00e9curit\u00e9 et l&#8217;efficacit\u00e9 \u00e0 long terme seront \u00e9valu\u00e9es pendant quatre ann\u00e9es suppl\u00e9mentaires apr\u00e8s l&#8217;ach\u00e8vement de l&#8217;essai initial, ce qui permettra d&#8217;obtenir des donn\u00e9es sur une p\u00e9riode totale de cinq ans apr\u00e8s le traitement par le LX2006.<br>LEXEO a annonc\u00e9 ce jour l&#8217;ach\u00e8vement de la premi\u00e8re cohorte de doses et l&#8217;administration de dose du premier patient de la deuxi\u00e8me cohorte de doses dans SUNRISE-FA.<br>Dans la premi\u00e8re cohorte de doses, LX2006 a \u00e9t\u00e9 bien tol\u00e9r\u00e9 et aucun \u00e9v\u00e9nement inattendu ou toxicit\u00e9 n&#8217;a \u00e9t\u00e9 observ\u00e9. Suite \u00e0 la recommandation du Comit\u00e9 de surveillance des donn\u00e9es de s\u00e9curit\u00e9 (DSMB ), les investigateurs ont commenc\u00e9 \u00e0 administrer les doses dans la deuxi\u00e8me cohorte.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pour plus d&#8217;informations sur l&#8217;essai, visitez le site www.clinicaltrials.gov en utilisant l&#8217;identifiant de l&#8217;\u00e9tude NCT05445323.<br>Le communiqu\u00e9 de presse est disponible sur<br><a href=\"https:\/\/www.lexeotx.com\/post\/lexeo-therapeutics-announces-completion-of-first-cohort-and-dosing-in-second-cohort-in-sunrise-fa-a-phase-1-2-clinical-trial-of-lx2006-for-the-treatment-of-friedreichs-ataxia-cardiomyopathy\/\" target=\"_blank\" rel=\"noreferrer noopener\">LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1\/2 Clinical Trial of LX2006 for the Treatment of Friedreich\u2019s Ataxia Cardiomyopathy &#8211; LEXEO Therapeutics (lexeotx.com)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>R\u00e9sum\u00e9 du communiqu\u00e9 de presseLEXEO Therapeutics (LEXEO) est une soci\u00e9t\u00e9 de th\u00e9rapie g\u00e9nique au stade clinique qui d\u00e9veloppe des candidats de th\u00e9rapie g\u00e9nique bas\u00e9s sur un virus ad\u00e9no-associ\u00e9 (AAV).LX2006 est la premi\u00e8re th\u00e9rapie g\u00e9nique exp\u00e9rimentale pour le traitement de la cardiomyopathie due \u00e0 l&#8217;ataxie de Friedreich.SUNRISE-FA est un essai ouvert multicentrique de phase 1\/2 de [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7805,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"ocean_front_end_style_editor":"no","ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"0","ocean_second_sidebar":"0","ocean_disable_margins":"enable","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"0","ocean_custom_header_template":"0","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"0","ocean_menu_typo_font_family":"0","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"0","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"off","ocean_gallery_id":[],"footnotes":""},"categories":[43],"tags":[],"class_list":["post-9021","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-informations_recherche","entry","has-media","owp-thumbs-layout-horizontal","owp-btn-normal","owp-tabs-layout-section","has-no-thumbnails"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\/06\/2023 - Association Fran\u00e7aise Ataxie de Friedreich<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\/06\/2023 - Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"og:description\" content=\"R\u00e9sum\u00e9 du communiqu\u00e9 de presseLEXEO Therapeutics (LEXEO) est une soci\u00e9t\u00e9 de th\u00e9rapie g\u00e9nique au stade clinique qui d\u00e9veloppe des candidats de th\u00e9rapie g\u00e9nique bas\u00e9s sur un virus ad\u00e9no-associ\u00e9 (AAV).LX2006 est la premi\u00e8re th\u00e9rapie g\u00e9nique exp\u00e9rimentale pour le traitement de la cardiomyopathie due \u00e0 l&#8217;ataxie de Friedreich.SUNRISE-FA est un essai ouvert multicentrique de phase 1\/2 de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-14T19:15:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T19:19:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3552\" \/>\n\t<meta property=\"og:image:height\" content=\"2365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"afafadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"afafadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/\"},\"author\":{\"name\":\"afafadmin\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/5424e5cbe70a962cadb85c217d565d80\"},\"headline\":\"Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\\\/06\\\/2023\",\"datePublished\":\"2023-06-14T19:15:34+00:00\",\"dateModified\":\"2023-06-14T19:19:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/\"},\"wordCount\":316,\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"articleSection\":[\"Informations sur la recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/\",\"name\":\"Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\\\/06\\\/2023 - Association Fran\u00e7aise Ataxie de Friedreich\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"datePublished\":\"2023-06-14T19:15:34+00:00\",\"dateModified\":\"2023-06-14T19:19:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"width\":3552,\"height\":2362},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/06\\\/14\\\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\\\/06\\\/2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"description\":\"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.afaf.asso.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"width\":1181,\"height\":709,\"caption\":\"Association Fran\u00e7aise Ataxie de Friedreich\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/5424e5cbe70a962cadb85c217d565d80\",\"name\":\"afafadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g\",\"caption\":\"afafadmin\"},\"sameAs\":[\"https:\\\/\\\/www.afaf.asso.fr\"],\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/author\\\/afafadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\/06\/2023 - Association Fran\u00e7aise Ataxie de Friedreich","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/","og_locale":"fr_FR","og_type":"article","og_title":"Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\/06\/2023 - Association Fran\u00e7aise Ataxie de Friedreich","og_description":"R\u00e9sum\u00e9 du communiqu\u00e9 de presseLEXEO Therapeutics (LEXEO) est une soci\u00e9t\u00e9 de th\u00e9rapie g\u00e9nique au stade clinique qui d\u00e9veloppe des candidats de th\u00e9rapie g\u00e9nique bas\u00e9s sur un virus ad\u00e9no-associ\u00e9 (AAV).LX2006 est la premi\u00e8re th\u00e9rapie g\u00e9nique exp\u00e9rimentale pour le traitement de la cardiomyopathie due \u00e0 l&#8217;ataxie de Friedreich.SUNRISE-FA est un essai ouvert multicentrique de phase 1\/2 de [&hellip;]","og_url":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/","og_site_name":"Association Fran\u00e7aise Ataxie de Friedreich","article_published_time":"2023-06-14T19:15:34+00:00","article_modified_time":"2023-06-14T19:19:42+00:00","og_image":[{"width":3552,"height":2365,"url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques.png","type":"image\/png"}],"author":"afafadmin","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"afafadmin","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/#article","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/"},"author":{"name":"afafadmin","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/5424e5cbe70a962cadb85c217d565d80"},"headline":"Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\/06\/2023","datePublished":"2023-06-14T19:15:34+00:00","dateModified":"2023-06-14T19:19:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/"},"wordCount":316,"publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","articleSection":["Informations sur la recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/","url":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/","name":"Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\/06\/2023 - Association Fran\u00e7aise Ataxie de Friedreich","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","datePublished":"2023-06-14T19:15:34+00:00","dateModified":"2023-06-14T19:19:42+00:00","breadcrumb":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/#primaryimage","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","width":3552,"height":2362},{"@type":"BreadcrumbList","@id":"https:\/\/www.afaf.asso.fr\/2023\/06\/14\/communique-de-presse-de-lexeo-therapeutics-du-13-03-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.afaf.asso.fr\/"},{"@type":"ListItem","position":2,"name":"Communiqu\u00e9 de presse de LEXEO Therapeutics du 13\/06\/2023"}]},{"@type":"WebSite","@id":"https:\/\/www.afaf.asso.fr\/#website","url":"https:\/\/www.afaf.asso.fr\/","name":"Association Fran\u00e7aise Ataxie de Friedreich","description":"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich","publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.afaf.asso.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.afaf.asso.fr\/#organization","name":"Association Fran\u00e7aise Ataxie de Friedreich","url":"https:\/\/www.afaf.asso.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","width":1181,"height":709,"caption":"Association Fran\u00e7aise Ataxie de Friedreich"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/5424e5cbe70a962cadb85c217d565d80","name":"afafadmin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g","caption":"afafadmin"},"sameAs":["https:\/\/www.afaf.asso.fr"],"url":"https:\/\/www.afaf.asso.fr\/author\/afafadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/9021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/comments?post=9021"}],"version-history":[{"count":0,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/9021\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media\/7805"}],"wp:attachment":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media?parent=9021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/categories?post=9021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/tags?post=9021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}